ArriVent Announces Cancer Cell Publication on Firmonertinib in EGFR-Mutant Lung Cancer
ArriVent announced publication of the Phase 1b FURTHER study on firmonertinib in EGFR PACC-mutant non-small cell lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
ArriVent Announces Cancer Cell Publication on Firmonertinib
The publication highlights firmonertinib in EGFR PACC-mutant non-small cell lung cancer.